Mindset Pharma’s CEO talks about new lead drug candidate MSP-1014, a potentially safer next generation psilocybin alternative used to assist people suffering from treatment-resistant depression.

Similar Posts

Interview with Dr. Erica Zelfand

Interview with Dr. Erica Zelfand

Listen, Podcasts

This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.

Numinus’ BIG Patent, Mydecine Tackles A $13.6 BILLION Market & Some BUY Ratings! ( NUMI / MYCO)

Numinus’ BIG Patent, Mydecine Tackles A $13.6 BILLION Market & Some BUY Ratings! ( NUMI / MYCO)

Listen, Videos

BIG news for Mydecine (MYCO : NEO) (MYCOF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF : OTC). But The BIGGER NEWS is that we are finally launching our website: https://thepsychedelicinvestor.com/, where we will be sharing the latest industry news for all of your favorite companies.
We hope we can facilitate our community’s path to information about the psychedelic sector. We would like to invite you to share your opinions and suggestions down in the comment section.

Last but not least, if you wish to collaborate and become a contributor for The Psychedelic Investor, you’re welcome to send us an email at thepsychedelicinvestor@gmail.com or fill in a form on our website! We welcome your opinion and you can have a shot at seeing your name in the opinion section of our website!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Links:

Numinus Wellness (TSXV: NUMI, OTC: LKYSF), Filed a Patent Application for their Proprietary Rapid Production Process of Psilocybe Mushrooms and Other Psychoactive Fungi Species:
https://thepsychedelicinvestor.com/2021/06/24/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species/

Mydecine (NEO: MYCO, OTC: MYCOF), Will Attempt To Treat Substance Use Disorder and Nicotine Addiction With Their MYCO-004 Molecule:
https://thepsychedelicinvestor.com/2021/06/24/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004/

Mydecine’s 4 Proprietary Compounds Advancing To Clinical Trials: Myco 001, 002, 003, 004:
https://thepsychedelicinvestor.com/2021/04/07/mydecine-announces-four-lead-novel-drug-candidates-and-prepares-for-pre-ind-meetings-with-the-fda-and-health-canada-to-prepare-for-human-clinical/

Johns Hopkins psilocybin study results:
https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html

Roth Capital Initiates Coverage On Mydecine Innovations with Buy Rating, Announces Price Target of 3$:
https://www.benzinga.com/news/21/06/21664391/roth-capital-initiates-coverage-on-mydecine-innovations-with-buy-rating-announces-price-target-of-c

Enjoy the episode!

Timestamps:
0:00 – Intro
1:37- Numinus’ patent application to speed up their psilobe mushrooms’ production process
4:53 – Mydecine announces it will use their MYCO – 004 molecule to treat substance use disorder and addiction
9:15 – Roth Capital says that Mydecine is a BUY with a price target of $3

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #Mydecine #NUMIStock

Interview with Joseph Mays, IRI Program Director at Chacruna

Interview with Joseph Mays, IRI Program Director at Chacruna

Listen, Podcasts

In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.